C4 Therapeutics presents cemsidomide Phase 1 data: 36% ORR in MM, 44% ORR in PTCL at ASH

C4 Therapeutics, Inc.

In MM with dexamethasone, 36% ORR and 45% CBR at 75 µg QD; no dose reductions due to AEs.
In NHL monotherapy, 38% ORR across subtypes; in PTCL, 44% ORR and 19% complete metabolic response rate.
Neutropenia manageable; no discontinuations due to neutropenia; MTD not yet reached.
Next steps: complete Phase 1 dose escalation, initiate combo trials, engage regulators on path.
Data support potential best-in-class IKZF1/3 degrader for MM and NHL.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.